Bloomberg
Lilly to Purchase Loxo Oncology in $8 Billion Deal
Jan.07 -- Eli Lilly & Co. will make its biggest takeover ever by acquiring Loxo Oncology Inc. in a deal worth about $8 billion in cash. Bloomberg's Rebecca Spalding reports on "Bloomberg Markets."
Bloomberg
Very Close to EU Budget Deal: European Investment Bank’s Hoyer
Nov.10 -- Werner Hoyer, president at European Investment Bank, discusses the European economy, the potential for a coronavirus vaccine, its impact on investment and the EU budget deal. He speaks on “Bloomberg Markets: European Open.”
Bloomberg
ICU Nurses Being Prioritized for Vaccine: Ascension CMO
Dec.14 -- Ascension Chief Medical Officer Dr. Joseph Cacchione says Pfizer Inc. has done "an incredible job" dealing with the logistical challenges posed by the distribution of the Covid-19 vaccine. He speaks on "Bloomberg Surveillance."
Bloomberg
Lightspeed Raises $7 Billion Across Four Funds
Lightspeed Venture Partners Partner Bejul Somaia speaks with Emily Chang about raising $7 billion across four new funds, where the company is planning to deploy capital, which founders and regions it's focusing on, and the debut of...
Bloomberg
BNP Paribas: 2022 to Be Year of Normalization for China
Jessica Tea, Greater China and Asia Pacific equities investment specialist at BNP Paribas Asset Management, discusses the outlook for Asian economies and the opportunities she sees in the region's markets. She also talks about the U.S....
Bloomberg
Biotech Executives Alarmed Over Trump Visa Crackdown
Feb.07 -- From tiny startups to global giants, the companies that sustain the $324 billion U.S. biotech industry are increasingly alarmed as President Donald Trump considers following his controversial travel ban with restrictions on...
Bloomberg
Lemkau: 2017 Will Be a Looser Regulatory Environment
Jan.09 -- Goldman Sachs Global Co-Head of M&A Gregg Lemkau discusses repatriation under the Trump administration, convergence in media and telecom, corporate tax cuts and trends to look for in 2017. He speaks on “Bloomberg Markets.â€
Bloomberg
Mustang Bio CEO on Next Steps for 'Bubble Boy' Cure
Apr.18 -- Manny Litchman, Mustang Bio Inc. chief executive officer, discusses the company's scientific breakthrough that cured eight infants suffering from the "Bubble Boy" immune system disorder. He speaks with Bloomberg's Caroline...
Bloomberg
I Think It’s Time to Sell Asia Biotech, Says Soochow’s Jackson
Jan.30 -- Andrew Jackson, head of Japanese equities at Soochow CSSD Capital Markets Asia, discusses SanBio’s 26% plunge, the biopharma rally in Asia and his outlook for the sector. He speaks on “Bloomberg Markets: Asia.”
Bloomberg
Sanofi to Buy Synthorx for $2.5 Billion
Dec.09 -- M&A Monday has begun with another big deal in the biotech space. Sanofi has agreed to buy U.S.-based Synthorx in a buyout worth approximately $2.5 billion. Bloomberg’s Sarah Syed reports on “Bloomberg Markets: European Open.”
Bloomberg
Biogen Will Take Alzheimer's Therapy to FDA, Reviving Hope
Oct.22 -- Biogen Inc. will ask U.S. drug regulators to approve the company’s experimental Alzheimer’s therapy, reviving the nearly abandoned treatment after a new analysis of data from two failed clinical trials showed promising results....
Bloomberg
Nasdaq CEO Friedman Sees Healthy IPO Pipeline Going Into Fall
Jul.24 -- Nasdaq CEO Adena Friedman discusses the health of the IPO market on "Bloomberg Markets: The Close."
Bloomberg
Why Pfizer Is Buying Array BioPharma for $10.6 Billion
Jun.17 -- Pfizer Inc. will buy Array BioPharma Inc. for $10.6 billion to gain its promising new medicines for cancer, which could end or limit the use of punishing chemotherapy for some patients. Bloomberg's Cynthia Koons reports on...
Bloomberg
Novavax Working Very Hard on Coronavirus Vaccine, R&D President Says
Jan.30 -- Dr. Gregory Glenn, Novavax president of research and development, discusses the efforts to contain the deadly coronavirus. He speaks with Bloomberg's Paul Allen and Taylor Riggs on "Bloomberg Markets."
Bloomberg
Trade-in value of Tesla cars holding up better than gas-powered cars: Ark's Cathie Wood
May.08 -- Cathie Wood, ARK Investment Management CEO & CIO, points to the negative effects of low oil prices on the trade-in value of gas-powered cars. She makes the case for adoption of electric vehicles by pointing to the sustained...
Bloomberg
Investing in Biotech is a Long Game: Schulman
Feb.26 -- Polaris Partners Managing Partner Amy Schulman says that the key to investing in biotech is to diversify by investing in a portfolio. She cautions that biotech investments can be risky, but says the successes are spectacular....
Bloomberg
Health Care, BioTech Are Highly Regulated Globally: Hutchmed
Jul.29 -- Christian Hogg, chief executive officer at Hutchmed, a cancer drug developer, discusses China’s regulatory crackdown, doing business in China and the outlook for the biotech sector. He speaks exclusively on “Bloomberg Daybreak:...
Bloomberg
Bristol Myers Plans to Launch Nine New Drugs, CEO Says
Bristol Myers Squibb Chairman and CEO Dr. Giovanni Caforio expects the company's new drugs to generate $10 billion to $13 billion in sales by 2025 and adds that the drugmaker is also looking at small and mid-size bolt-on deals to add to...
Bloomberg
Biden Signs Inflation Reduction Act Into Law
Ginkgo Bioworks CEO Jason Kelly joins Emily Chang to discuss how the new climate and tax bill, now signed into law, will impact the biotech space. Plus, his thoughts on which post-pandemic trends to watch for, how he feels about children...
Bloomberg
Google Ventures CEO Maris on A.I., Theranos, Biotech & VC
June 14 -- Bill Maris, Google Ventures chief executive officer, comments on artificial intelligence's impact on biotech, the prospects for Theranos and the venture capital environment. He speaks with Bloomberg's Emily Chang from the...
Bloomberg
Morgan Stanley's Parker: Biotech Is Mispriced and a Buy
Sept. 26 -- Adam Parker, chief U.S. equity strategist at Morgan Stanley, discusses biotech stocks and political risk ahead of the election with Bloomberg's Scarlet Fu, Tracy Alloway and Joe Weisenthal on "What'd You Miss?"
Bloomberg
OrbiMed's Isaly: Biotech Slump 'Has Been Overdone'
June 29 -- Samuel Isaly, managing partner at OrbiMed Advisors, discusses the slump in biotech stocks, what he focuses on when evaluating companies, and his M&A outlook. He speaks on "Blomberg Markets." (Corrects spelling of company name...
Bloomberg
8VC's Lonsdale on Health Tech, VC and Immigration
May.11 -- Joe Lonsdale, 8VC founding partner and Palantir Technologies founder, discusses technology's impact on health care, the state of the VC market and U.S. immigration policy. He speaks with Bloomberg's Mike McKee on "What'd You...
Bloomberg
Stick With China’s Largest Pharma Guys, Says Citigroup’s Yung
Jul.23 -- John Yung, head of Asia healthcare research at Citigroup, discusses China’s healthcare sector, the possibility of an expansion to the drug procurement program, consolidation and his outlook for the industry. He speaks on...